Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze

被引:21
作者
Vorhees, Charles V. [1 ]
Johnson, Holly L.
Burns, Lindsey N.
Williams, Michael T.
机构
[1] Univ Cincinnati, Cincinnati Childrens Res Fdn, Dept Pediat, Div Neurol, Cincinnati, OH 45229 USA
基金
美国国家卫生研究院;
关键词
Quinpirole; Dopamine D2/3 receptors; Dopamine D2/3 agonist; Learning and memory; Spatial learning; Development; Rat; NEONATAL METHAMPHETAMINE EXPOSURE; ADULTHOOD NICOTINE TREATMENT; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; GENETIC-DIFFERENCES; TASK-PERFORMANCE; MEMORY DEFICITS; RATS; SCHIZOPHRENIA; NEUROPATHOLOGY; CORTICOSTERONE;
D O I
10.1016/j.ntt.2008.09.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Developmental exposure to the dopamine D2/3 receptor agonist quinpirole is reported to induce D2 priming, impair Morris water maze performance, reduce acoustic startle prepulse inhibition (PPI), and alter locomotor activity. We treated rats from postnatal days 1-21 with the dose reported to induce these effects, 1.0 mg/kg/day, and two higher doses, 2.0 and 4.0 mg/kg/day, or saline. Offspring were tested in the Morris water maze, PPI, exploratory locomotor activity, activity after quinpirole and (+)-methamphetamine challenge, elevated zero maze, light-dark box, marble burying, straight channel swimming, and Cincinnati water maze. In the Morris water maze, all quinpirole groups had longer latencies on test days 3-5 of acquisition, but no effects on reversal or shifted-reduced platform trials. The quinpirole 4.0 mg/kg group had significantly reduced mean search distances on probe trials when combined across the 3 phases of testing but not separately. The male 4.0 mg/kg quinpirole group showed a greater increase in methamphetamine-stimulated activity during the first 10 min after drug challenge but not in the remainder of the 2 h test. No quinpirole effects were found for light-dark box, marble burying, exploratory locomotor activity, straight channel, Cincinnati water maze, or locomotor activity after quinpirole challenge. No effects were found on most measures in the elevated zero maze however the quinpirole 4.0 mg/kg females had longer latencies to enter an open quadrant. The results partially support prior Morris maze deficits induced by developmental quinpirole treatment but little evidence of dopamine D2/3 priming was found using locomotor activity with quinpirole or methamphetamine challenge or acoustic startle/PPI. The limited comparability to published data using developmental quinpirole exposure may be attributable to differences in experimental procedures or may be the result of quinpirole having limited effects. The data suggest that caution is warranted concerning the developmental efficacy of quinpirole. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
    Yan, Yinfa
    Zhou, Ping
    Rotella, David P.
    Feenstra, Rolf
    Kruse, Chris G.
    Reinders, Jan-Hendrik
    van der Neut, Martina
    Lai, Margaret
    Zhang, Jean
    Kowal, Dianne M.
    Carrick, Tikva
    Marquis, Karen L.
    Pausch, Mark H.
    Robichaud, Albert J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2983 - 2986
  • [32] D2/3 Agonist during Learning Potentiates Cued Risky Choice
    Mortazavi, Leili
    Hynes, Tristan J.
    Chernoff, Chloe S.
    Ramaiah, Shrishti
    Brodie, Hannah G.
    Russell, Brittney
    Hathaway, Brett A.
    Kaur, Sukhbir
    Winstanley, Catharine A.
    JOURNAL OF NEUROSCIENCE, 2023, 43 (06) : 979 - 992
  • [33] Sex differences in high fat diet-induced impairments to striatal Akt signaling and enhanced sensitivity to the behavioral effects of dopamine D2/D3 receptor agonist quinpirole
    Ramos, Jeremiah
    Hernandez-Casner, Caroline
    Cruz, Bryan
    Serafine, Katherine M.
    PHYSIOLOGY & BEHAVIOR, 2019, 203 : 25 - 32
  • [34] Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats
    Breuer, Megan E.
    Groenink, Lucianne
    Oosting, Ronald S.
    Buerger, Erich
    Korte, Michiel
    Ferger, Boris
    Olivier, Berend
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 616 (1-3) : 134 - 140
  • [35] Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression
    Veselinovic, Tanja
    Paulzen, Michael
    Gruender, Gerhard
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (11) : 1141 - 1159
  • [37] BREXPIPRAZOLE: A NEW DOPAMINE D2 RECEPTOR PARTIAL AGONIST FOR THE TREATMENT OF SCHIZOPHRENIA AND MAJOR DEPRESSIVE DISORDER
    Citrome, L.
    DRUGS OF TODAY, 2015, 51 (07) : 397 - 414
  • [38] (+/-)3,4-Methylenedioxymethamphetamine (MDMA) Dose-Dependently Impairs Spatial Learning in the Morris Water Maze after Exposure of Rats to Different Five-Day Intervals from Birth to Postnatal Day Twenty
    Vorhees, Charles V.
    Schaefer, Tori L.
    Skelton, Matthew R.
    Grace, Curtis E.
    Herring, Nicole R.
    Williams, Michael T.
    DEVELOPMENTAL NEUROSCIENCE, 2009, 31 (1-2) : 107 - 120
  • [39] Effect of lead (Pb2+) exposure in female pregnant rats and their offspring on spatial learning and memory in Morris water maze
    Soodi, Maliheh
    Naghdi, Nasser
    Sharifzadeh, Mohammad
    Ostad, Seyed Nasser
    Abdollahi, Mohammad
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2008, 7 (01): : 43 - 51
  • [40] Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
    Batinic, Borjanka
    Ristic, Ivan
    Zugic, Milica
    Baldwin, David S.
    FRONTIERS IN PSYCHIATRY, 2021, 12